title: Bone remodeling and calcium homeostasis in patients with spinal cord injury: a review.
abstract: Patients with spinal cord injury exhibit early and acute bone loss with the major functional consequence being a high incidence of pathological fractures. The bone status of these patients is generally investigated by dual-energy x-ray absorptiometry, but this technique does not reveal the pathophysiological mechanism underlying the bone loss. Bone cell activity can be indirectly evaluated by noninvasive techniques, including measurement of specific biochemical markers of bone formation (such as osteocalcin or bone-alkaline phosphatase) and resorption (such as procollagen type I N- or C-terminal propeptide). The bone loss in spinal cord injury is clearly due to an uncoupling of bone remodeling in favor of bone resorption, which starts just after the injury and peaks at about 1 to 4 months. Beyond 6 months, bone resorption activity decreases progressively but remains elevated for many years after injury. Conversely, bone formation is less affected. Antiresorptive treatment induces an early and acute reduction in bone resorption markers. Level of injury and health-related complications do not seem to be implicated in the intensity of bone resorption. During the acute phase, the hypercalcemic status is associated with the suppression of parathyroid hormone and vitamin D metabolites. The high sensitivity of these markers after treatment suggests that they can be used for monitoring treatment efficacy and patient compliance. The concomitant use of bone markers and dual-energy x-ray absorptiometry may improve the physician's ability to detect patients at risk of severe bone loss and subsequent fractures.
authors.affiliation: Département d'Hormonologie, Hôpital Lapeyronie, CHU Montpellier and UMI, 34295 Montpellier, France. l-maimoun@chu-montpellier.fr
authors.forename: Laurent
authors.initials: L
authors.lastname: Maïmoun
authors.forename: Charles
authors.initials: C
authors.lastname: Fattal
authors.forename: Charles
authors.initials: C
authors.lastname: Sultan
mesh_terms: D015502:Absorptiometry, Photon; D000208:Acute Disease; D000469:Alkaline Phosphatase / Q000378:metabolism; D015415:Biomarkers / Q000097:blood; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D016723:Bone Remodeling; D001862:Bone Resorption / Q000209:etiology / Q000378:metabolism* / Q000517:prevention & control / Q000628:therapy*; D002116:Calcitonin / Q000378:metabolism; D002118:Calcium / Q000378:metabolism* / Q000627:therapeutic use*; D024042:Collagen Type I / Q000378:metabolism; D003131:Combined Modality Therapy; D004599:Electric Stimulation Therapy; D005081:Exercise Therapy; D005598:Fractures, Spontaneous / Q000209:etiology / Q000517:prevention & control; D006706:Homeostasis; D006801:Humans; D015675:Osteocalcin / Q000378:metabolism; D010012:Osteogenesis; D010264:Paraplegia / Q000209:etiology / Q000378:metabolism; D010281:Parathyroid Hormone / Q000378:metabolism; D011237:Predictive Value of Tests; D011782:Quadriplegia / Q000209:etiology / Q000378:metabolism; D012307:Risk Factors; D012680:Sensitivity and Specificity; D013119:Spinal Cord Injuries / Q000097:blood / Q000150:complications* / Q000378:metabolism*; D013997:Time Factors; D014807:Vitamin D / Q000008:administration & dosage / Q000378:metabolism
chemical_list: D015415:Biomarkers; D050071:Bone Density Conservation Agents; D024042:Collagen Type I; D010281:Parathyroid Hormone; D015675:Osteocalcin; D014807:Vitamin D; D002116:Calcitonin; D000469:Alkaline Phosphatase; D002118:Calcium